Test Name: *HLA-B27 DISEASE ASSOCIATION
Test Code: 2191584
Alias: Ankylosing Spondylitis
B27 Disease Association
Disease Association Testing
LAB869
CPT Code(s): 81374  
Test Includes:

*Note: This test may require notification/prior authorization by insurance companies. Check the patient's insurance plan for qualifications prior to submitting testing.  If authorization is required, please submit with the test request.
Preferred Specimen: 4.0 mL whole blood
Container:

EDTA (lavender)

Minimum Volume:
0.5 mL whole blood (Note: This volume does not allow for repeat testing.)
Collection Instructions:

Invert tube 5 to 10 times immediately after filling.
Transport Temperature: Room temperature
Stability: Room temperature: 30 days
Rejection Criteria:

Hemolysis

Clotted specimen

Tube other than lavender- top (EDTA) tube
Limitations:

Regarding whole blood specimens, an adequate test requires the presence of intact lymphocytes at the time of testing. Even taking appropriate precautions, an occasional specimen will not be satisfactory for testing. In such cases, fresh blood should be drawn for retesting.

This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA).
Additional Information: HLA-B27 is strongly associated with ankylosing spondylitis (Marie-Strumpell disease). HLA-B27 shares homology with a Klebsiella protein and may imply a bacterial pathogenesis to ankylosing spondylitis. A patient with consistent clinical and radiographic findings who is B27-positive has a greater chance of having or developing ankylosing spondylitis than a negative patient. The antigen is not causative, however, and 10% of normal subjects are B27-positive. This test should not be considered a screening procedure for ankylosing spondylitis. The antigen is less strongly associated with Reiter syndrome and other arthritides than with ankylosing spondylitis. It has been linked with congenital deficiency of C4 and C2, and with adrenal hyperplasia.
Schedule: TAT: Report available in 3-7 days from receipt of specimen at LabCorp
Method:

Polymerase Chain Reaction (PCR)/Sequence Specific Oligonucleotide Probes (SSOP)

This test is a class I antigen level test.
Performing Lab:

LabCorp; #006924
Clinical Significance: Evaluate spondyloarthritis and other disorders associated with HLA-B27
Use: Updated 2/22/22

The CPT codes included in this publication are in accordance with Current Procedural Terminology, a publication of the American Medical Association. CPT codes are provided here for the convenience of our clients; however, correct coding often varies from one carrier to another, and HealthLab may bill specific carriers using codes other than those shown. Clients who bill for services should verify the code(s) with the applicable payor to confirm that their use is appropriate in each case.
Test Type:

FIND A HEALTHLAB LOCATION

LOCATION ADDRESS

HOURS OF OPERATION